糖尿病罹患胰腺癌相关临床特征分析

Related clinical characteristics of diabetes patients suffering from pancreatic cancer

目的观察分析糖尿病患者罹患胰腺癌的临床特征。方法选取107例胰腺癌患者(分为非糖尿病合并胰腺癌组66例和糖尿病合并胰腺癌组41例)和100例糖尿病未合并胰腺癌者(糖尿病正常对照组),比较人口学信息、肿瘤分化程度、血清学指标等资料;分析糖尿病患者罹患胰腺癌的可能相关临床特征。结果 (1)107例胰腺癌患者以中老年男性为主,血糖代谢异常患者占55.1%,其中,空腹血糖受损18例(16.8%),合并糖尿病41例(38.3%);(2)糖尿病合并胰腺癌组和非糖尿病合并胰腺癌组比较,糖尿病合并胰腺癌患者具有更易出现体质量减轻、症状隐匿的特征(P<0.05);(3)糖尿病合并胰腺癌组和非糖尿病合并胰腺癌组患者血清指标比较,糖尿病合并胰腺癌患者空腹血糖、γ-谷氨酰基转移酶水平明显增高(P<0.05);(4)糖尿病合并胰腺癌组和糖尿病正常对照组比较,糖尿病合并胰腺癌组患者具有年龄较大、病程较短和体质量指数较轻的特征(P<0.05);且更易出现体质量减轻(P<0.05);血清糖类抗原19-9(CA19-9)、癌胚抗原(CEA)水平明显增高(P<0.05)。结论年长、病程较短、体质量指数较轻糖尿病患者是罹患胰腺癌的高危人群;临床上表现为症状隐匿、体质量减轻等特征;CA19-9、CEA是发现糖尿病患者罹患胰腺癌的敏感指标。

Objective To observe and analyze clinical characteristics of diabetes patients suffering from pancreatic cancer. Methods We recruited 107 cases of pancreatic cancer（66 without diabetes and 41 with diabetes） and 100 diabetes patients without pancreatic pancreas as control, Patients＇ demographic information, degree of tumor differentiation, serum markers etc. were compared in order to find out the relevant clinical features of diabetes patients suffering from pancreatic cancer. Results （1） Patients with pancreatic cancer mostly were middle-aged males. 55.1% of them suffering from dysglycemia, 18 （16.8% ） and 41 （38.3 % ） of whom had impaired fasting glucose and diabetes, respectively. （2）Compared with their without diabetes counterparts, pancreatic cancer with diabetes were more prone to he asymptomatic and weight loss （P〈 0.05）. （3）Compared with their without diabetes counterparts,pancreatic cancer with diabetes had significantly higher levels of fasting blood glucose（FBG） and y-glutamyltranspeptidase （7-GT）（P〈0.05）. （4）When compared with diabetes control, pancreatic cancer with diabetes were older and shorter duration and lower body mass index（BMI）（P〈0.05）. They were more prone to weight loss（P〈0.05）. Moreover,serum CA19-9 and CEA levels in them were significantly higher than those in the diabetes control（P〈0.05）. Conclusion Older age,shorter duration,low BMI are all risk factors for diabetes patients to develop pancreatic cancer. Being asymptomatic and weight loss are their clinical characteristics. CA19-9 and CEA are both sensitive serum markers to detect pancreatic cancer patients with diabetes.